



## Univercells signs Letters of Intent for two bioproduction projects in Senegal, strengthening Belgo-Senegalese collaborations to advance access to biologics for all

Namur, Belgium, April 13<sup>th</sup>, 2021

Minister-President of Wallonia, Elio Di Rupo has the honor of welcoming today His Excellency, Macky Sall, President of Senegal and prominent Senegalese institutions in public health to meet with Univercells and advance collaborations in line with Senegal's scientific development and public health goals, bolstering Senegal's public health ambitions.

Accompanying the Senegalese Political Delegation to meet Univercells S.A. ("Univercells") were the Institute for Health Research, Epidemiological Surveillance and Training ("IRESSEF") and the Institut Pasteur de Dakar ("IPD"). Both IRESSEF and IPD have facilities in Diamniadio, near Dakar. Emerging as a hub for biotechnology in Senegal and West Africa at large, with these two bilateral collaborations Univercells is working to strengthen the local technological capacity for ongoing bioproduction and biomedical research with international partners.

IRESSEF is a non-profit, public institute, working closely with local research institutes, universities, as well as governmental and non-governmental organizations across Africa and beyond. Univercells and IRESSEF signed a Letter of Intent ("LoI") to work together to create bioproduction capacity, alongside strengthening of the research and development capabilities of IRESSEF. This collaboration would be focused on vaccines for routine immunization in Senegal.

Institut Pasteur de Dakar (IPD) is a leading biomedical research and public health Institute in Senegal and Africa with a proven expertise on fighting emerging diseases to protect public health and promote disease surveillance. IPD is the only WHO pre-qualified manufacturer vaccine in Africa and has been manufacturing vaccines for 80 years. The COVID-19 pandemic, as well as the emergence of novel variants have underlined the importance of dedicated supply of needed health products. Univercells and IPD signed a second LoI outlining Univercells' support for a consortium, led by IPD, to rapidly establish local bioproduction of COVID-19 vaccines and leveraging the proprietary manufacturing solutions from Univercells Technologies.

These two separate projects demonstrate the strategic importance of Senegal as a hub for biotechnology on the African continent. All parties have expressed enthusiasm about the long-term potential for Belgo-Senegalese collaborations. Univercells remains committed to innovation and partnerships, pursuing its mission of making biologics available to all. It is our hope that this collaboration is a significant milestone in the relationship between our organization and African countries.

### ●●● About Univercells ●●●

Univercells is a global life sciences company that makes biologics available to all. Leveraging our core strengths in scaling, production, and bioprocessing, we build businesses and find new ways to support access to medicines and promote sustainability. Through entrepreneurship and technology-driven affordability, we address the needs of the entire health value chain.

Univercells is headquartered in Gosselies (Belgium) and benefits from the support of regional and national investors, as well as international investors, such as the Bill & Melinda Gates Foundation, EIB, Global Health Investment Fund, among others active in the health and vaccine industry.

[www.univercells.com](http://www.univercells.com)

### ●●● Disclosure Statement ●●●

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.